Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Paredes

Showing results (181-190 of 309) with videos related to

Pageof 31
Sort By:
AIDS Research and Human Retroviruses|April 21, 2006
Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patientsAnna Bonjoch, Roger Paredes, Pere Domingo, et al.
Communications Medicine|December 8, 2025
Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1._Lucia Bailón, Yovaninna Alarcón-Soto, José R Arribas, et al.
Viruses|December 23, 2023
The Role of Late Presenters in HIV-1 Transmission Clusters in EuropeMafalda N S Miranda, Victor Pimentel, Perpétua Gomes, et al.
Microbiome|May 13, 2019
Evolution of the gut microbiome following acute HIV-1 infectionMuntsa Rocafort, Marc Noguera-Julian, Javier Rivera, et al.
The Journal of Infectious Diseases|December 25, 2012
Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failureJonathan Z Li, Roger Paredes, Heather J Ribaudo, et al.
Nature Communications|March 4, 2026
Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trialFrancesc Català-Moll, Carlos Blázquez-Bondia, Judit Farré-Badia, et al.
Nature Communications|April 27, 2026
Author Correction: Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trialFrancesc Català-Moll, Carlos Blázquez-Bondia, Judit Farré-Badia, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2026
Baseline resistance mutations and virological response to dolutegravir in treatment-naïve patients: a multicentre NGS studyAlexy Inciarte, Leire Berrocal, José R Santos, et al.
AIDS Research and Human Retroviruses|September 14, 2017
A Summary of the Second Annual HIV Microbiome WorkshopBrett Williams, Mimi Ghosh, Charles A B Boucher, et al.
The Journal of Antimicrobial Chemotherapy|October 23, 2015
Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequencesJosé Ramón Santos, José Luis Blanco, Mar Masiá, et al.
Pageof 31

Showing results (181-190 of 309) with videos related to

Sort By:
Pageof 31
AIDS Research and Human Retroviruses|April 21, 2006
Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patientsAnna Bonjoch, Roger Paredes, Pere Domingo, et al.
Communications Medicine|December 8, 2025
Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1._Lucia Bailón, Yovaninna Alarcón-Soto, José R Arribas, et al.
Viruses|December 23, 2023
The Role of Late Presenters in HIV-1 Transmission Clusters in EuropeMafalda N S Miranda, Victor Pimentel, Perpétua Gomes, et al.
Microbiome|May 13, 2019
Evolution of the gut microbiome following acute HIV-1 infectionMuntsa Rocafort, Marc Noguera-Julian, Javier Rivera, et al.
The Journal of Infectious Diseases|December 25, 2012
Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failureJonathan Z Li, Roger Paredes, Heather J Ribaudo, et al.
Nature Communications|March 4, 2026
Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trialFrancesc Català-Moll, Carlos Blázquez-Bondia, Judit Farré-Badia, et al.
Nature Communications|April 27, 2026
Author Correction: Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trialFrancesc Català-Moll, Carlos Blázquez-Bondia, Judit Farré-Badia, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2026
Baseline resistance mutations and virological response to dolutegravir in treatment-naïve patients: a multicentre NGS studyAlexy Inciarte, Leire Berrocal, José R Santos, et al.
AIDS Research and Human Retroviruses|September 14, 2017
A Summary of the Second Annual HIV Microbiome WorkshopBrett Williams, Mimi Ghosh, Charles A B Boucher, et al.
The Journal of Antimicrobial Chemotherapy|October 23, 2015
Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequencesJosé Ramón Santos, José Luis Blanco, Mar Masiá, et al.
Pageof 31